Aeglea Doses First Patient In Phase I Study Of AEB1102 For Treatment Of Solid Tumors

-- Top-Line Data is Expected in 2016 --

AUSTIN, Texas--(BUSINESS WIRE)--Aeglea BioTherapeutics, Inc., a biopharmaceutical company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer, today announced the dosing of the first patient in a Phase 1 open-label dose escalation study of its lead investigational molecule, AEB1102, for the treatment of patients with advanced solid tumors. The study will assess the safety, tolerability and pharmacokinetics of AEB1102.

“The dosing of the first patient in this study of AEB1102 is a major milestone for Aeglea as we continue to advance our development pipeline”

“The dosing of the first patient in this study of AEB1102 is a major milestone for Aeglea as we continue to advance our development pipeline,” said David G. Lowe, Ph.D., co-founder, president and chief executive officer. “We are looking forward to collecting this important data around the clinical profile of AEB1102 as we take the next step in our mission to address critical unmet medical needs in patients with cancer and inborn errors of metabolism.”

About AEB1102

AEB1102 is an engineered human enzyme designed to degrade the amino acid arginine and in nonclinical studies has demonstrated the ability to reduce blood arginine levels. AEB1102 is being developed to treat cancers that are predicted to have a metabolic dependency on arginine, as well as the rare disease Arginase I deficiency, which is caused by an inborn error of metabolism leading to toxic levels of arginine in blood.

About Aeglea BioTherapeutics

Aeglea is a biopharmaceutical company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer. The company’s engineered human enzymes are designed to degrade specific amino acids in the blood in order to reduce toxic levels of amino acids in inborn errors of metabolism or to exploit the dependence of certain cancers on specific amino acids. In addition to clinical development in oncology, Aeglea’s lead product candidate AEB1102 is expected to begin clinical trials in 2016 in patients with Arginase I deficiency. The company is building a pipeline of additional product candidates targeting key amino acids, including AEB4104, which degrades homocysteine, a target for an inborn error of metabolism, as well as two potential treatments for cancer, AEB3103, which degrades cysteine/cystine, and AEB2109, which degrades methionine.

For more information, visit http://aegleabio.com.